Enveric Biosciences, Inc.
ENVB
$1.21
-$0.08-6.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.23M | 1.24M | 1.30M | 1.93M | 685.90K |
| Depreciation & Amortization | 82.50K | 84.80K | 84.80K | 85.40K | 84.70K |
| Other Operating Expenses | -246.10K | -- | -- | -- | -107.20K |
| Total Operating Expenses | 3.17M | 2.08M | 1.90M | 2.48M | 2.38M |
| Operating Income | -3.17M | -2.08M | -1.90M | -2.48M | -2.38M |
| Income Before Tax | -3.15M | -2.08M | -1.88M | -2.46M | -3.41M |
| Income Tax Expenses | 7.20K | -- | -- | 1.70K | 22.30K |
| Earnings from Continuing Operations | -3.15M | -2.08M | -1.88M | -2.46M | -3.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.15M | -2.08M | -1.88M | -2.46M | -3.44M |
| EBIT | -3.17M | -2.08M | -1.90M | -2.48M | -2.38M |
| EBITDA | -3.09M | -2.00M | -1.81M | -2.39M | -2.30M |
| EPS Basic | -4.80 | -3.59 | -3.72 | -9.21 | -22.56 |
| Normalized Basic EPS | -2.99 | -2.25 | -2.32 | -5.75 | -14.01 |
| EPS Diluted | -4.80 | -3.59 | -3.72 | -9.21 | -22.56 |
| Normalized Diluted EPS | -2.99 | -2.25 | -2.32 | -5.75 | -14.01 |
| Average Basic Shares Outstanding | 657.40K | 580.20K | 505.90K | 266.80K | 152.30K |
| Average Diluted Shares Outstanding | 657.40K | 580.20K | 505.90K | 266.80K | 152.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |